An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)

Background: Recent cost-utility analysis (CUA) models for onasemnogene abeparvovec (Zolgensma®, formerly AVXS-101) in spinal muscular atrophy type 1 (SMA1) differ on key assumptions and results. Objective: To compare the manufacturer’s proprietary CUA model to the model published by the Institute fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Dean, Rebecca, Jensen, Ivar, Cyr, Phil, Miller, Beckley, Maru, Benit, Sproule, Douglas M., Feltner, Douglas E., Wiesner, Thomas, Malone, Daniel C., Bischof, Matthias, Toro, Walter, Dabbous, Omar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919869/
https://www.ncbi.nlm.nih.gov/pubmed/33708361
http://dx.doi.org/10.1080/20016689.2021.1889841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919869/
https://www.ncbi.nlm.nih.gov/pubmed/33708361
http://dx.doi.org/10.1080/20016689.2021.1889841

Ejemplares similares